Recently, a new group of molecules, named SPMs that resolve inflammation were elucidated. Further, in efforts to investigate and demonstrate their mechanism of action, their receptors are slowly being discovered. As an additional milestone, SPMs were detected in several biological samples. However, the investigation of the pharmacological principle based on GPCR for SPMs under various physiological and pathological conditions is insufficient (Psychogios et al. 2011; Lukiw et al. 2005). Further research is needed on specific molecular targets of omega-3 fatty acids such as RvE2, RvD2, PDs, and MaRs. The interaction between the host immune system and infectious viral attacks represents new opportunities for the utilization of SPMs. The use of SPMs is likely to help regulate abnormal viral-mediated inflammation and prevent complications such as SARS-CoV-2 cytokine storm. Besides, SPMs play parts in restoring tissue homeostasis, including wound healing. Therefore, they are very likely to have therapeutic effects against the sequelae of SARS-CoV-2 infection. Both inflammation and resolution of inflammation are vital processes of the immune system. Therefore, a balance between the need for a sufficient immune response to clear the infection and the rapid decline of immune response to prevent host damage presents a novel opportunity for therapeutic exploitation of the SPMs.